MGI Pharma MOGN New patents, anti cancer Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : MGI Pharma MOGN New patents, anti cancer

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Icebrg who wrote (1644)	3/11/2006 2:09:54 AM
From: Icebrg	of 1826

MGI Pharma "neutral," target price reduced Friday, March 10, 2006 2:56:03 AM ET Robert W. Baird NEW YORK, March 10 (newratings.com) - Analysts at Robert W Baird reiterate their "neutral" rating on MGI Pharma Inc (MOGN.NAS), while reducing their estimates for the company. The target price has been reduced from $20 to $19. In a research note published yesterday, the analysts mention that American Pharmaceutical Partners (APPX) has received a tentative approval for generic Zofran from the FDA. APPX intends to launch the generic after Zofran's patent expires in December. According to the analysts, the launch would significantly affect the sales of MGI Pharma’s Aloxi drug sales from early 2007. The EPS estimate for 2007 has been reduced from $0.83 to $0.76.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next